Non-Hodgkin's Lymphoma in Patients with Systemic Lupus Erythematosus

Papadaki, Helen Α.; Xylouri, Irene; Katrinakis, G; Foudoulakis, A; Kritikos, H; Stathopoulos, Efstathios N.; Boumpas, D T; Eliopoulos, George D.

doi:10.1080/1042819021000030045

Cited by 7 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The long-term exposure to the myelosuppressive agent methotrexate might be a contributing factor affecting the bone marrow erythroid cell reserve and function in rheumatoid arthritis patients. The patients' bone marrow erythropoiesis was improved following anti-TNF-α treatment without discontinuing MTX, fact that indicates that TNF-α is the major factor affecting the erythroid development in RA [32].…”

Section: Rheumatoid Arthritismentioning

confidence: 98%

“…Effective TNF-α neutralization by infliximab in vivo improves anemia of chronic disease (ACD) in RA by reducing apoptosis in the erythroid progenitor and precursor cell compartments [32]. The long-term exposure to the myelosuppressive agent methotrexate might be a contributing factor affecting the bone marrow erythroid cell reserve and function in rheumatoid arthritis patients.…”

Section: Rheumatoid Arthritismentioning

confidence: 99%

See 1 more Smart Citation

Biological Therapies of Autoimmune Diseases

Kourbeti

Boumpas²

2005

CDTIA

View full text Add to dashboard Cite

The advances in the understanding of the pathogenesis of the autoimmune diseases have led to new treatment targets. Biological agents enhance or replace conventional immunosuppressive therapies in the treatment of autoimmune diseases. TNF-alpha has been validated as a good treatment target but the potential modalities also include the inhibition of the interaction between LFA-3 (lymphocyte function-associated antigen 3) and CD2, the blockade of the IL-1 receptors, the antibodies against the alpha4 integrins, the antibodies against B-cell CD20 and the inhibition of the activation of T-cells. The new treatments have had a major impact on inflammatory symptoms, the radiological damage and the anemia of chronic disease in rheumatoid arthritis and have substantially controlled the signs and symptoms in the spondylarthropathies group and plaque-type psoriasis. The efficacy of the biologic agents in systemic lupus erythematosus warrants further investigation but there have been some promising results in proliferative lupus nephritis. Several small studies have explored their use in the treatment of Sjogren's syndrome, adult onset Still's disease and several vasculitides but the results are still preliminary and warrant confirmation. The efficacy of the biological agents has been impressive. Susceptibility to infections has always been a major concern; a high level of suspicion is necessary and strategies should be implemented for the prevention, the rapid identification and pre-emptive therapy of such infections.

show abstract

Section: Rheumatoid Arthritismentioning

confidence: 98%

Section: Rheumatoid Arthritismentioning

confidence: 99%

Biological Therapies of Autoimmune Diseases

Kourbeti

Boumpas²

2005

CDTIA

View full text Add to dashboard Cite

show abstract

“…Infrequently, the diagnosis of malignancy precedes the appearance of systemic lupus erythematosus 134,142,156,158,159,161,185 . In addition, the concomitant onset of both diseases, or the detection of systemic lupus erythematosus and malignancy within a period of 12 months, occasionally occurs 134,142,148–150,161,175,184 …”

Section: Systemic Lupus Erythematosusmentioning

confidence: 99%

Granuloma annulare, relapsing polychondritis, sarcoidosis, and systemic lupus erythematosus: conditions whose dermatologic manifestations may occur as hematologic malignancy‐associated mucocutaneous paraneoplastic syndromes

Cohen¹

2006

Int J Dermatology

View full text Add to dashboard Cite

IntroductionThe appearance of certain dermatoses has heralded either the diagnosis of a previously unsuspected malignancy or the detection of cancer recurrence in an oncology patient. 1,2 These associated mucosal and cutaneous conditions are referred to as mucocutaneous paraneoplastic syndromes. 3 In this issue, Zappasodi et al . 4 review some of the mucocutaneous paraneoplastic syndromes that occur in patients with hematologic malignancies. Albeit less commonly, other dermatologic conditions and systemic disorders can also occur in a paraneoplastic setting associated with hematologic malignancies: granuloma annulare, relapsing polychondritis, sarcoidosis, and systemic lupus erythematosus. Granuloma AnnulareGranuloma annulare is a chronic dermatosis of undetermined etiology. Clinically, the skin lesions present as flesh-colored to red papules and small nodules, which appear either as individual lesions or as an annular arrangement of confluent lesions. Mucin-containing areas of necrobiotic collagen in the dermis are surrounded by palisading granulomas consisting of epithelioid histiocytes, lymphocytes, and multinucleated giant cells.Granuloma annulare can be localized to a specific area of the body or generalized. Perforating and subcutaneous variants of the condition may also occur. Several factors have been described to precipitate the development of granuloma annulare: sunburn, drug eruption, flu-like illness, trauma, insect bites, and acute phlebitis. In addition, granuloma annulare has been observed in patients with potentially associated diseases -particularly diabetes mellitus and thyroid disease, but also drug allergy, hypertension, obesity, arthritis, atopy, sarcoidosis, and human immunodeficiency virus infection. [5][6][7][8][9] Skin lesions of leukemia or lymphoma that histopathologically mimic granuloma annulare have also been described in patients with hematologic malignancies. 10-14 Cancer-associated granuloma annulare has been reported predominantly in patients with hematologic malignancies (most commonly non-Hodgkin's lymphoma and Hodgkin's disease) and, less often, in individuals with solid tumors (Table 1). 5,6,[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33] Relapsing PolychondritisRelapsing polychondritis is a multisystemic disorder characterized by recurrent inflammation and degeneration of cartilaginous tissues -particularly those of the ears, nose, larynx, and trachea. [34][35][36][37] The dermatologic manifestations of relapsing polychondritis are variable and include aphthosis [oral and complex (genital)], nodules (on the extremities), purpura, papules, sterile pustules, superficial phlebitis, livedo reticularis, ulcers (on the extremities), and distal necrosis. 38 The aorta, bone, bronchi, central nervous system, ears, eyes, genitals, heart valves, kidneys, larynx, mouth, nose, and trachea are potential sites of extracutaneous involvement in patients with relapsing polychondritis. 34,38,39 The diagnostic criteria for relapsing polychondritis were initially e...

show abstract

“…Insbesondere kann die Ursache-Wirkung-Beziehung nicht sicher bestimmt werden, eine reine Koinzidenz erscheint jedoch unwahrscheinlich [1,18]. Verschiedene Erklärungsan-sätze, die neben den Erkrankungen selbst, Alter und Geschlecht, mögliche genetische und virale Einflussfaktoren, Lifestyle-und Umweltfaktoren aber auch die antiinflammatorische und immunsuppressive Therapie diskutieren, werden kontrovers beurteilt [2,5,6,9,[19][20][21][22].…”

Section: Introductionunclassified

Die Rationale für Knochenmarkuntersuchungen bei Patienten mit entzündlich-rheumatischen Erkrankungen

Gossen

Germing

Blum

et al. 2009

Wien Klin Wochenschr

View full text Add to dashboard Cite

One third of our patients showed relevant bone marrow changes that might be associated to therapy. The risk seems to be increased especially in patients with inflammatory rheumatic diseases who had received azathioprine alone or in combination with cyclophosphamide. Health care providers should bear in mind the risk of hematologic malignancies and monitor patients closely in this respect. Bone marrow examination should be performed in case of changes in peripheral blood counts; especially clinically relevant anemia, granulocytes < 2,500/microl, thrombocytes < 100,000/microl and relevant changes over time should lead to bone marrow examinations.

show abstract

Non-Hodgkin's Lymphoma in Patients with Systemic Lupus Erythematosus

Cited by 7 publications

References 22 publications

Biological Therapies of Autoimmune Diseases

Biological Therapies of Autoimmune Diseases

Granuloma annulare, relapsing polychondritis, sarcoidosis, and systemic lupus erythematosus: conditions whose dermatologic manifestations may occur as hematologic malignancy‐associated mucocutaneous paraneoplastic syndromes

Die Rationale für Knochenmarkuntersuchungen bei Patienten mit entzündlich-rheumatischen Erkrankungen

Contact Info

Product

Resources

About